TY - JOUR
T1 - PCOS patients can benefit from in vitro maturation (IVM) of oocytes
AU - Shalom-Paz, Einat
AU - Holzer, Hananel
AU - Young Son, Weon
AU - Levin, Ishai
AU - Tan, Seang Lin
AU - Almog, Benny
PY - 2012/11
Y1 - 2012/11
N2 - Objective: Our aim was to compare treatment outcome following in vitro maturation (IVM) compared with IVF in patients with polycystic ovarian syndrome (PCOS). Study design: Retrospective evaluation of treatment in women with PCOS who underwent IVM (108) and IVF (108). Results: We found a significant difference in outcome between IVM and IVF, with an increase in the number of mature oocytes derived (10.5 ± 6.5 vs. 15.3 ± 8.8, p < 0.0001) and the cleavage rate (92.4 ± 13.0 vs. 95.2 ± 11.7, p = 0.03) in IVM cycles. Due to the lower implantation rate (16.1% vs. 21.6%, p = 0.07) we tend to transfer more embryos in the IVM group (3.4 ± 0.8 vs. 2.8 ± 1.0, p < 0.0001), but the multiple pregnancy rate in that group was not higher. Importantly, the delivery rate was similar in both groups (26.8% vs. 25%). We also report a yearly change in the success rate of IVM during this period. Conclusions: IVM treatment for PCOS patients may be a valid alternative treatment to IVF with the advantage of eliminating the risk of OHSS and reducing the cost of medication, whilst maintaining high clinical pregnancy rate.
AB - Objective: Our aim was to compare treatment outcome following in vitro maturation (IVM) compared with IVF in patients with polycystic ovarian syndrome (PCOS). Study design: Retrospective evaluation of treatment in women with PCOS who underwent IVM (108) and IVF (108). Results: We found a significant difference in outcome between IVM and IVF, with an increase in the number of mature oocytes derived (10.5 ± 6.5 vs. 15.3 ± 8.8, p < 0.0001) and the cleavage rate (92.4 ± 13.0 vs. 95.2 ± 11.7, p = 0.03) in IVM cycles. Due to the lower implantation rate (16.1% vs. 21.6%, p = 0.07) we tend to transfer more embryos in the IVM group (3.4 ± 0.8 vs. 2.8 ± 1.0, p < 0.0001), but the multiple pregnancy rate in that group was not higher. Importantly, the delivery rate was similar in both groups (26.8% vs. 25%). We also report a yearly change in the success rate of IVM during this period. Conclusions: IVM treatment for PCOS patients may be a valid alternative treatment to IVF with the advantage of eliminating the risk of OHSS and reducing the cost of medication, whilst maintaining high clinical pregnancy rate.
KW - Delivery rate
KW - In vitro fertilization
KW - In vitro maturation
KW - PCOS
UR - http://www.scopus.com/inward/record.url?scp=84869082820&partnerID=8YFLogxK
U2 - 10.1016/j.ejogrb.2012.07.001
DO - 10.1016/j.ejogrb.2012.07.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 22819571
AN - SCOPUS:84869082820
SN - 0301-2115
VL - 165
SP - 53
EP - 56
JO - European Journal of Obstetrics and Gynecology and Reproductive Biology
JF - European Journal of Obstetrics and Gynecology and Reproductive Biology
IS - 1
ER -